- Home
- OPI vs GOVX Comparison
OPI vs GOVX Comparison
Compare OPI & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPI
- GOVX
- Stock Information
- Founded
- OPI 2009
- GOVX 2001
- Country
- OPI United States
- GOVX United States
- Employees
- OPI N/A
- GOVX N/A
- Industry
- OPI Real Estate Investment Trusts
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- OPI Real Estate
- GOVX Health Care
- Exchange
- OPI Nasdaq
- GOVX Nasdaq
- Market Cap
- OPI 17.7M
- GOVX 15.5M
- IPO Year
- OPI 2009
- GOVX N/A
- Fundamental
- Price
- OPI $0.21
- GOVX $0.95
- Analyst Decision
- OPI
- GOVX Strong Buy
- Analyst Count
- OPI 0
- GOVX 5
- Target Price
- OPI N/A
- GOVX $12.40
- AVG Volume (30 Days)
- OPI 1.4M
- GOVX 1.5M
- Earning Date
- OPI 07-30-2025
- GOVX 08-05-2025
- Dividend Yield
- OPI 17.72%
- GOVX N/A
- EPS Growth
- OPI N/A
- GOVX N/A
- EPS
- OPI N/A
- GOVX N/A
- Revenue
- OPI $476,159,000.00
- GOVX $5,591,576.00
- Revenue This Year
- OPI N/A
- GOVX N/A
- Revenue Next Year
- OPI N/A
- GOVX N/A
- P/E Ratio
- OPI N/A
- GOVX N/A
- Revenue Growth
- OPI N/A
- GOVX N/A
- 52 Week Low
- OPI $0.18
- GOVX $0.73
- 52 Week High
- OPI $3.02
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- OPI 40.92
- GOVX 46.22
- Support Level
- OPI $0.18
- GOVX $0.85
- Resistance Level
- OPI $0.30
- GOVX $1.39
- Average True Range (ATR)
- OPI 0.02
- GOVX 0.15
- MACD
- OPI 0.01
- GOVX -0.02
- Stochastic Oscillator
- OPI 18.18
- GOVX 18.52
About OPI Office Properties Income Trust of Beneficial Interest
Office Properties Income Trust is a United States-based real estate investment trust. Its property portfolio is mainly composed of single-tenant office buildings, as well as multitenant properties, which are leased to parties of high credit quality characteristics. Its major tenant is the U.S. government, followed by other smaller government entities and corporations. The company's properties are spread across the United States. The company has only one segment which is direct ownership of real estate properties.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.